Antagonistic synergy: Process and paradox in the development of new agricultural antimicrobial regulations
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Antagonistic synergy : Process and paradox in the development of new agricultural antimicrobial regulations. / Dean, Wesley R.; Scott, H. Morgan.
I: Agriculture and Human Values, Bind 22, Nr. 4, 2005, s. 479-489.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antagonistic synergy
T2 - Process and paradox in the development of new agricultural antimicrobial regulations
AU - Dean, Wesley R.
AU - Scott, H. Morgan
PY - 2005
Y1 - 2005
N2 - There is currently great controversy over the contribution antimicrobial use in animal agriculture has made to antimicrobial resistance in pathogenic bacteria with negative consequences for human health. In light of this, the approval process for antimicrobials used in US animal agriculture, known as New Animal Drug Application or NADA, is currently being revised by the federal government. We explore the public deliberations over the development of these new policies focusing our attention on the interaction between pharmaceutical companies and the U.S. Food and Drug Administration. What appears to be an antagonistic public discourse is examined in terms of its ability to simultaneously legitimate the roles of the Food and Drug Administration as the official arbiter of policy on antimicrobial use in animal agriculture and as a protector of the public welfare, as well as the role of pharmaceutical companies as the producers of safe and effective products necessary for the protection of public well-being.
AB - There is currently great controversy over the contribution antimicrobial use in animal agriculture has made to antimicrobial resistance in pathogenic bacteria with negative consequences for human health. In light of this, the approval process for antimicrobials used in US animal agriculture, known as New Animal Drug Application or NADA, is currently being revised by the federal government. We explore the public deliberations over the development of these new policies focusing our attention on the interaction between pharmaceutical companies and the U.S. Food and Drug Administration. What appears to be an antagonistic public discourse is examined in terms of its ability to simultaneously legitimate the roles of the Food and Drug Administration as the official arbiter of policy on antimicrobial use in animal agriculture and as a protector of the public welfare, as well as the role of pharmaceutical companies as the producers of safe and effective products necessary for the protection of public well-being.
KW - Antibiotics
KW - Antimicrobials
KW - Drug policy
KW - Food and Drug Administration
KW - Pharmaceutical companies
KW - State theory
U2 - 10.1007/s10460-005-3403-y
DO - 10.1007/s10460-005-3403-y
M3 - Journal article
AN - SCOPUS:30044445900
VL - 22
SP - 479
EP - 489
JO - Agriculture and Human Values
JF - Agriculture and Human Values
SN - 0889-048X
IS - 4
ER -
ID: 255457669